FDA considers ending animal testing for key drug development stages
The US Food and Drug Administration (FDA) has signalled a potential shift away from animal testing in drug development. Marty Makary, a senior FDA official, highlighted that modern science now provides more effective and humane alternatives. His comments have sparked discussions among researchers and animal welfare advocates alike.
Makary proposed reducing or eliminating some primate tests for monoclonal antibodies, which are used in treatments for cancer, Crohn’s disease, and other conditions. He argued that computational modelling and other advanced methods could replace these tests, cutting drug development time and costs.
The FDA’s stance could accelerate changes in drug testing protocols. If computational models and other alternatives prove successful, fewer animals may be needed in future research. The shift may also streamline drug approvals and reduce costs for pharmaceutical companies.
